A practical reference on mass spectrometry: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-01. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
In 1996, the US had about 2 deaths per 10,000 motor vehicles, compared to 1.9 in Germany, 2.6 in France, and 1.5 in the UK. In 1998, there were 3,421 fatal crashes in the UK, the fewest since 1926; in 2010, this number was further reduced to 1,857 and was attributed to the 2009–2010 scrappage scheme. The sizable traffic safety lead enjoyed by the US since the 1960s had narrowed significantly by 2002, with the US improvement percentages lagging in 16th place behind those of Australia, Austria, Canada, Denmark, Finland, Germany, United Kingdom, Iceland, Japan, Luxembourg, the Netherlands, New Zealand, Norway, Sweden, and Switzerland in terms of deaths per thousand vehicles, while in terms of deaths per 100 million vehicle miles travelled, the US had dropped from first place to tenth place. Transportation safety in the United States is monitored by various agencies.
Industrial breeding of plants has unintentionally altered how agricultural cultivars associate with their microbiome. In maize, for example, breeding has altered the nitrogen cycling taxa required to the rhizosphere, with more modern lines recruiting less nitrogen fixing taxa and more nitrifiers and denitrifiers. Microbiomes of breeding lines showed that hybrid plants share much of their bacterial community with their parents, such as Cucurbita seeds and apple shoot endophytes. In addition, the proportional contribution of the microbiome from parents to offspring corresponds to the amount of genetic material contributed by each parent during breeding and domestication.
Vantin (by Pfizer) in suspension or tablet form. Toraxim (by Delta Pharma Ltd., Bangladesh) Trucef (by Renata Limited, Bangladesh) Tricef (by Alkaloid Skopje, North Macedonia) Orelox (by Sanofi-Aventis) MAPDOX-CV: Combination cefpodoxime–clavulanic acid MONOTAX O (cefpodoxime)/MONOTAX CV (cefpodoxime–clavulanic acid) by Zydus Healthcare Ltd. ACXIME 200/CV (by Allencia Biosciences, India) POSTPOD-50 (cefpodoxime 50mg/5ml) by Laafon Galaxy Pharmaceuticals
1 June – Caltech reports the first successful beaming of solar energy from space down to a receiver on the ground, via the MAPLE instrument on its SSPD-1 spacecraft, launched into orbit in January. 2 June – Physicist Lucas Lombriser proposes a controversial alternative way of interpreting the available scientific data which suggests that the notion of an expanding universe may be more a "mirage" than otherwise. 5 June Scientists report potential evidence that Homo naledi, an extinct species of small-brained archaic human discovered in 2013 in South Africa, and living as long as 500,000 years ago, buried their dead, created art in their caves and used fire. A 'chef' robot developed is trained to watch and learn from cooking videos, and recreate dishes itself. A first global estimate suggests that an equivalent of ~36% of current annual CO2 emissions from fossil fuels is stored by soil mycelium of mycorrhizal fungi yearly. 6 June – A study finds that the first complete disappearance of Arctic sea ice could occur during the 2030s, a decade earlier than previously forecast. 7 June – Scientists report a new mechanism of central nervous system viral diseases including COVID-19 – fusion of brain cells. 8 June US scientists confirm that the next El Niño has begun, likely resulting in higher global temperatures in late 2023 and into 2024. Various statistics show the year is unusual and climate change is already having significant impacts such as an Antarctic sea ice extent anomaly and record-high ocean surface temperatures.
Sources: en.wikipedia.org
In engineering, the elasticity of a material is quantified by the elastic modulus such as the Young's modulus, bulk modulus or shear modulus which measure the amount of stress needed to achieve a unit of strain; a higher modulus indicates that the material is harder to deform. The SI unit of this modulus is the pascal (Pa). The material's elastic limit or yield strength is the maximum stress that can arise before the onset of plastic deformation. Its SI unit is also the pascal (Pa).
All lepidosaurs and turtles have a three-chambered heart consisting of two atria, one variably partitioned ventricle, and two aortas that lead to the systemic circulation. The degree of mixing of oxygenated and deoxygenated blood in the three-chambered heart varies depending on the species and physiological state. Under different conditions, deoxygenated blood can be shunted back to the body or oxygenated blood can be shunted back to the lungs. This variation in blood flow has been hypothesized to allow more effective thermoregulation and longer diving times for aquatic species, but has not been shown to be a fitness advantage.
In June 2011, the twelfth edition of the National Toxicology Program (NTP) Report on Carcinogens (RoC) changed the listing status of formaldehyde from "reasonably anticipated to be a human carcinogen" to "known to be a human carcinogen." Concurrently, a National Academy of Sciences (NAS) committee was convened and issued an independent review of the draft US EPA IRIS assessment of formaldehyde, providing a comprehensive health effects assessment and quantitative estimates of human risks of adverse effects.
Sources: en.wikipedia.org
catalyst Any chemical species or substance whose presence increases the reaction rate of one or more particular chemical reactions but which is itself unchanged by the reaction, being neither a reactant nor a product of the reaction. Catalysts often need only be present in very low concentrations relative to the reactants in order for catalysis to occur. They may be simple molecules which catalyze reactions spontaneously, though most biochemical reactions are catalyzed by specifically evolved enzymes which allow them to proceed at rates millions or billions of times faster than they otherwise would.
In North America, Canada and the United States represent an unusual case in the Western world in that they were not governed by a socialist party at the federal level. However, the democratic socialist Co-operative Commonwealth Federation (CCF), the precursor to the social democratic New Democratic Party (NDP), had significant success in provincial Canadian politics. In 1944, the Saskatchewan CCF formed the first socialist government in North America and its leader Tommy Douglas is known for having spearheaded the adoption of Canada's nationwide system of universal healthcare called Medicare. At the federal level, the NDP was the Official Opposition (2011–2015).
Clinical and Vaccine Immunology (CVI) was a peer-reviewed journal published by the American Society for Microbiology. CVI enhances our understanding of the immune response in health and disease by showcasing important clinically relevant research, including new animal models for human immunologic diseases, viral immunology, immunopathogenesis, and clinical laboratory immunology. In particular, the journal highlights important discoveries in immunization and vaccine research, such as the development and evaluation of vaccines, human and animal immune responses to vaccines, vaccine vectors, adjuvants and immunomodulators, quantitative assays of vaccine efficacy, and clinical trials. The journal publishes primary research articles, editorials, commentaries, minireviews, and case reports. Articles are freely accessible after six months (delayed open access). Through its "Global Outreach Program", free online access is available to qualified microbiologists in eligible developing countries.
== Preparation == Esterification is the general name for a chemical reaction in which two reactants (typically an alcohol and an acid) form an ester as the reaction product. Esters are common in organic chemistry and biological materials, and often have a pleasant characteristic, fruity odor. This leads to their extensive use in the fragrance and flavor industry. Ester bonds are also found in many polymers.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.